Search
for
Sort by
Research 30 of 104
- Persistently curly hair phenotype with the use of nivolumab for squamous cell lung cancer
- Nivolumab-Induced Alopecia Areata: A Case Report and Literature Review
- Resolution of paraneoplastic alopecia areata following nivolumab in a patient with metastatic melanoma
- A case of bullous pemphigoid in a malignant melanoma patient following an increased Th2/Th1 ratio in peripheral blood cells after nivolumab treatment
- Anti-programmed cell death protein 1-induced lichenoid changes of the nail unit: Histopathologic description
- Eosinophilic folliculitis of the scalp associated with PD‐1/PDL1 inhibitors
- Cutaneous Toxicities of Advanced Treatment for Cutaneous Melanoma: A Prospective Study from a Single-Center Institution
- Immune Cell-Targeting Biologics for Alopecia Areata: A New Paradigm in Precision Medicine
- Cemiplimab-Induced Alopecia Areata
- ODP342 Panhypopituitarism Induced by CTLA-4 and PD-1/PD-L1 Inhibitor Immunotherapy
- A bibliometric study of the top 100 most cited articles on melanoma: insights into research trends and characteristics
- 15460 Perifollicular pink halo: A potential dermoscopic marker of inflammation in central centrifugal cicatricial alopecia
- Biological therapy in the treatment of melanoma
- Decreased benzothiazole-type pheomelanin in regrown brown hair in alopecia areata
- BH14 Multiple sclerosis and alopecia areata: drug-induced alopecia areata or coexisting autoimmune phenomena?
- Skin toxicity induced by chemotherapy or molecular targeted therapy combined with immune checkpoint inhibitors in Asian patients: A literature review by the Japanese Pharmacist-led Oncodermatology Study Team
- Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
- Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors
- Hair disorders in patients with cancer
- Autoimmunity and autoimmune co-morbidities in psoriasis
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Alopecia in Association with Malignancy: A Review
- A comparative analysis of immune privilege in pregnancy and cancer in the context of checkpoint blockade immunotherapy
- Cancer Treatments and Alopecia: A Systematic Review
- Dermatologic Adverse Events from Cancer Treatments
- Management of Toxicities of Targeted Therapies
- Leflunomide: an unlikely trigger and mechanistically a beneficial drug for alopecia areata
- Adverse Hair Reactions to New Targeted Therapies for Cancer
- Industry update: the latest developments in the field of therapeutic delivery, July 2018
- Premature Hair Graying: Underlying Contributors and Management Approaches - An Updated Literature Review